Today, Prohost is highlighting news that could be transformative for a clinical-stage immunotherapy firm. The firm with promising news focuses on creating and developing safer and far-reaching Chimeric Antigen Receptor T-cell (CAR T) Therapy.
The firm we are highlighting today is Celyad (CYAD), whose investigational CAR T products are allogeneic, rather than autologous, which makes it easier to use and less expensive than the autologous products. The firm’s CAR T products are meant to improve the safety of the current CAR T therapy, while enabling the . . .
This content is for paid subscribers.
Today’s Highlights October 5, 2018